🔗 Share this article

While America continues making unprecedented adjustments to its immunization recommendations, one figure has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccines during the global health crisis and has focused upon possible fatalities after Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Schedule

Health officials were set to announce sweeping revisions to the pediatric immunization program recently, synchronizing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of alignment with many the world with insufficient data for improved outcomes. This reveal has been postponed until the coming year.

In place of Vinay Prasad, Dr. Høeg is set to present at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to head the office this year.

Consolidating Power at the Agency

The acting appointment could signify a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has often pushed for ending certain childhood vaccine recommendations in the US to become more similar to the Danish model, a society with universal health coverage and a citizenry about the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has no obvious track record in drug development, approval processes or administrative roles, which has been typical for past directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She appears not to have the necessary background” for leading the CDER, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in running a sizeable institution. She has no expertise in drug approvals.”

Previous directors of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that prior appointees who led CBER have had.”

This division has an immense portfolio at the agency, Woodcock pointed out.

“Many people just focuses on the new drug program, but the generic drug division clears a multitude of generic drugs. There’s a biosimilars division, OTC medication office and more, and all of those have to be looked after,” Dr. Woodcock noted. “The thing you overlook, that is the part that I always told people is going to cause problems.”

There is also, a substantial management element to the role, which supervises in excess of 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” she concluded.

Response and Controversial Policies

When asked about concerns about Dr. Høeg's fitness for the role and whether this selection represents more teamwork among agency officials on vaccines, a spokesperson stated that the “concerns rely on flawed presumptions”.

“This background aligns with the responsibilities of her job,” the spokesperson explained, pointing to the period Høeg spent advising the agency head on “medication safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial one-day therapy clearance system that allegedly troubled her preceding directors. “By what process are these therapies being selected for this voucher program? Who is making the calls?” Dr. Howard questioned. “There’s a lot of confidentiality going on at the FDA right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards less stringent rules of all drugs, aside from immunizations.”

Established Past Work on Immunizations

Regarding immunizations, Høeg has a more established, if troubling, track record, critics have noted. She released a study using unverified public submissions to determine the rate of myocarditis following COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the new government featured revising guidelines for new vaccines and discontinuing “optional” immunizations, she remarked after the election on a audio program. At the agency, Dr. Høeg has allegedly suggested preventing adolescent males from receiving COVID-19 vaccinations.

“She is an all-around dogmatist who commences with her beliefs and works backwards to fit the evidence in a highly misleading, fraudulent manner,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg joined other contrarians, {like|